Long-term results of conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy in locoregionally advanced carcinoma of the oropharynx

Tumori

Volumn 92, Issue 1, 2006, Pages 41-54

  Fallai, Carlo ^a   Bolner, Andrea ^b   Signor, Marco ^c   Gava, Alessandro ^d   Franchin, Giovanni ^e   Ponticelli, Pietro ^f   Taino, Raffaella ^g   Rossi, Francesca ^h   Ardizzoia, Alessandro ⁱ   Oggionni, Maria ^a   Crispino, Sergio ^j   Olmi, Patrizia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Radioterapia Oncologica   (Italy)

^c Azienda Ospedaliero Universitaria Santa Maria della Misericordia   (Italy)

^d OSPEDALE CA FONCELLO   (Italy)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^f IRCCS POLICLINICO SAN DONATO   (Italy)

^g OSPEDALI RIUNITI   (Italy)

^h Radioterapia   (Italy)

ⁱ AO S Gerardo   (Italy)

^j USL 7   (Italy)

more..

Author keywords

Advanced squamous cell oropharyngeal carcinoma; Altered fractionation; Concomitant radiochemotherapy; Radiation therapy; Randomized phase III trial

Indexed keywords

CARBOPLATIN; FLUOROURACIL;

ACUTE TOXICITY; ADULT; ADVANCED CANCER; AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SECOND CANCER; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TREATMENT FAILURE; XEROSTOMIA;

EID: 33646004893     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160609200108     Document Type: Article

References (86)

1. Million RR: Cancer of the head and neck. In: Principles and practice of oncology, De Vita VT, Hellman S, Rosenberg SA (Eds), pp 396-420, Lippincott-Raven, Philadelphia, 1992.
2. Olmi P, Cellai E, Chiavacci A, Fallai C: Results of curative radiotherapy in oropharyngeal carcinomas. Rays, 11: 138-139, 1985.
3. Sanchiz F, Millà A, Torner J, Bonet F, Artola N, Careno L, Moya LM, Riera D, Ripol S, Cirera L: Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys, 21: 557-562, 1990.
4. Pinto LHJ, Canary PCV, Araujo CMM, Bacelar SC, Souhami L: Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys, 21: 557-562, 1991.
5. Horiot JC, Le Fur R, N'Guyen T, Chenal C, Schraub S, Alfonsi S, Gardani G, Van Den Bogaert W, Danczak S, Bolla M, Van Glabbeke M, De Pauw M: Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol, 25: 231-241, 1992.
6. Wang CC: Local control of oropharyngeal carcinoma after two accelerated hyperfractionation radiation therapy schemes. Int J Radiat Oncol Biol Phys, 14: 1143-1146, 1988.
7. Vokes E, Weichselbaum RR: Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol, 8: 911-934, 1989.
8. Adelstein DJ, Sharan VM, Earle AS, Shah AC, Vlastou C, Haria CD, Carter SG, Damm C, Hines JD: Long-term results after radiochemotherapy for locally confined squamous-cell head and neck cancer. Am J Clin Oncol, 13: 440-447, 1990.
9. Merlano M, Vitale V, Rosso R, Merlano M, Vitale V, Rosso R, Benasso M, Corvo R, Cavallari M, Sanguineti G, Bacigalupo A, Badellino F, Margarino G, Brema F, Pastorino G, Marziano C, Grimaldi A, Scasso F, Sperati G, Pallestrini E, Garaventa G, Accomando E, Cordone G, Comella G, Daponte A, Rubagotti A, Bruzzi P, Santi L: Treatment of advanced squamous-cell carcinoma of the head and neck. N Engl J Med, 327: 1115-1121, 1992.
10. Taylor IV SG, Murthy AK, Vannetzel JM, Colin P, Dray M, Caldarelli DD, Shott S, Vokes E, Showel JL, Hutchinson JC: Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol, 12: 385-395, 1994.
11. Olmi P, Crispino S, Fallai C, Torri V, Rossi F, Bolner A, Amichetti M, Signor M, Taino R, Squadrelli M, Colombo A, Ardizzoia A, Ponticelli P, Franchin G, Minatel E, Gobitti C, Atzeni G, Gava A, Flann M, Marsoni S: Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy - a multicenter randomized trial. Int J Radiat Oncol Biol Phys, 55: 78-92, 2003.
12. th ed, Springer Verlag, New York, 1989.
13. RTOG/EORTC Late Radiation Morbidity Scoring Schema. Radiation Therapy Oncology Group website, 2004. Available at: http://www.rtog.org/members/toxicity/late.html. Accessed August 1, 2005.
14. Bourhis J, Syz N, Overgard J, Ang KK, Dische S, Horiot JC, Hilniak A, Poulsen M, O'Sullivan B, Dobrowsky W, Fallai C, Pinto L, Skladowski K, Hay JH, Fu KK, Sylvester R, Pignon J: Conventional versus modified fractionated radiotherapy. Meta-analysis of radiotherapy in head and neck squamous cell carcinoma: a meta-analysis based on individual patient data. Int J Radiat Oncol Biol Phys, 54 (Suppl 1): S71-72, 2002.
15. Bourhis J, Etessami A, Wilbault P, Lusinchi A, Calais G, Lapeyre M, Pignon JP: Altered fractionated radiotherapy in the management of head and neck carcinomas: advantages and limitations. Curr Opin Oncol, 16: 215-219, 2004.
16. Bourhis J, Audry H, Overgaard J. Ang K, Dische S, Horiot J, Hliniak A, O'Sullivan B, Dobrowsky W, Skladowski K, Fallai C, Hay J: Meta-analysis of conventional versus altered fractionated radiotherapy in head and neck squamous cell carcinoma (HNSCC): final analysis. Int J Radiat Oncol Biol Phys, 60 (Suppl 1): S190-191, 2004.
17. Overgaard J, Hansen AS, Specht L, Overgaard M, Grau C, Andersen E, Bentzen J, Bastholt L, Hansen O, Johansen J, Andersen L, Evensen JF: Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial. Lancet, 362: 933-940, 2003.
18. Bourhis J, Lapeyre M, Tortochaux J, Rive M, Lesaunie P, Benassi T, Lemanski C, Bardet E, Wibault P, Benhamou E: Very accelerated compared to conventional radiotherapy in HN-SCC: long-term results of a GORTEC phase III randomized trial. (Abstr) ESTRO 23 2004: S16. ESTRO website, 2004. Available at http://www.estroweb.org/ESTRO/upload/abstractbooks/2AbstractbookESTRO23.pdf. Accessed July 31, 2005.
19. Rosenthal DI, Ang KK: Altered radiation therapy fractionation, chemoradiation, and patient selection for the treatment of head and neck squamous carcinoma. Sem Radiat Oncol, 14: 153-166, 2004.
20. Pignon JP, Bourhis J, Domenge C, Designe L: Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of Chemotherapy on Head and Neck Cancer. Lancet, 355: 949-955, 2000.
21. Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J Natl Cancer Inst, 91: 2081-2086, 1999.
22. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Calais G: Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol, 22: 69-76, 2004.
23. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Calais G: Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys, 55: 93-98, 2003.
24. Calais G, Bardet E, Sire C, Alfonsi M, Bourhis J, Rhein B, Tortochaux J, Man YT, Auvray H, Garaud P: Radiotherapy with concomitant weekly docetaxel for stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC phase II trial. Int J Radiat Oncol Biol Phys, 58: 161-166, 2004.
25. Semrau R, Mueller R, Stuetzer H, Schroeder U, Staar S, Rudat V, Dietz A, Volling P, Schroeder M, Flentje M, Eckel H: Ceiling effect of hemoglobin (Hb)-levels increasing efficacy of intensified hyperfractionated (HF) and accelerated (ACC) radiotherapy (RT) and concurrent chemotherapy with carboplatin and 5-FU. Updated results of a randomized multicentric German trial in advanced head and neck cancer. Int J Radiat Oncol Biol Phys, 60 (Suppl 1): S191, 2004.
26. Bensadoun R, Benezery K, Ramaioli A, Magne N, Lemanski C, Tortochaux J, Bourdin S, Dassonville O, Milano G, Schneider M, Calais G, Demard F: Phase III multicenter randomized study of concurrent twice-a-day radiotherapy with and without cisplatin-5FU (BiRCF) in unresectable pharyngeal carcinoma. 24 months results (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys, 60 (Suppl 1): S161, 2004.
27. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys, 48: 7-16, 2000.
28. Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere A: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol, 21: 92-98, 2003.
29. Brizel DM, Prosnitz RG, Hunter S, Fisher SR, Clough RL, Downey MA, Scher RL: Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys, 58: 1418-1423, 2004.
30. Porceddu SV, Jarmolowski E, Hicks RJ, Ware R, Weih L, Rischin D, Corry J, Peters LJ: Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck, 27: 175-181, 2005.
31. Greven KM: Positron-emission tomography for head and neck cancer. Sem Radiat Oncol, 14: 121-129, 2004.
32. Corvò R, Benasso M, Sanguineti G, Lionetto R, Bacigalupo A, Margarino G, Pallestrini E, Merlano M, Vitale V, Rosso R: Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck: results from a phase III randomized trial. Cancer, 92: 2856-2867, 2001.
33. Jeremic B, Milicic B, Dagovic A, Vaskovic Z, Tadic L: Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck. J Clin Oncol, 22: 3540-3548, 2004.
34. Bourhis J, Lapeyre M, Tortochaux J, Emessami A, Wibault P, Geoffrois L, Vergelle P, Domenge C, Auperin A: Preliminary resuls of the GORTEC 96-01 randomized trial, comparing vey accelerated radiotherapy versus concomitant radiochemotherapy for locally inoperable HNSCC. Int J Radiat Oncol Biol Phys, 51 (Suppl 1): S39, 2001.
35. Bieri S, Bentzen SM, Huguenin P, Allal AS, Cozzi L, Landmann C, Monney M, Bernier J: Early morbidity after radiotherapy with or without chemotherapy in advanced head and neck cancer. Experience from four nonrandomized studies. Strahlenther Onkol, 179: 390-395, 2003.
36. Benasso M, Lionetto R, Covò R, Ponzanelli A, Vitale V, Rosso R: Impact of the treating institution of patients with head and neck cancer treated with concomitant alternating chemotherapy and radiation. Eur J Cancer, 39: 1895-1898, 2003.
37. Chow TL, Chow TK, Chan TT, Yu NF, Fung SC, Lam SH: Contralateral neck recurrence of squamous cell carcinoma of oral cavity and oropharynx. J Oral Maxillofac Surg, 62: 1225-1228, 2004.
38. Kagei K, Shirato H, Nishioka T, Arimoto T, Hashimoto S, Kaneko M, Ohmori K, Honma A, Inuyama Y, Miyasaka K: Ipsilateral irradiation for carcinomas of tonsillar region and soft palate based on computed tomographic simulation. Radiother Oncol, 54: 117-121, 2000.
39. O'Sullivan B, Warde P, Grice B, Goh C, Payne D, Liu FF, Waldron J, Bayley A, Irish J, Gullane P, Cummings B: The benefits and pitfalls of ipsilateral radiotherapy in carcinoma of the tonsillar region. Int J Radiat Oncol Biol Phys, 51: 332-343, 2001.
40. Claus F, Duthoy W, Boterberg T, Huys J, Vermeersch H, Braems S, Bonte K, Moerman M, Verhoye C, De Neve W: Intensity modulated radiation therapy for oropharyngeal and oral cavity tumors: clinical use and experience. Oral Oncology, 38: 597-604, 2002.
41. Chao KS, Ozyigit G, Blanco AI, Thorstad WL, Deasy JO, Haughey BH, Spector GJ, Sessions DG: Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys, 59: 43-50, 2004.
42. Garden AS, Morrison WH, Rosenthal DI, Chao KS, Ang KK: Target coverage for head and neck cancers treated with IM-RT: review of clinical experiences. Sem Rad Oncol, 14: 103-109, 2004.
43. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res, 62: 7350-7356, 2002.
44. Milas L, Fan Z, Andratschke NH, Ang KK: Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys, 58: 966-971, 2004.
45. Warnakulasuriya KA, Robinson D, Evans H: Multiple primary tumours following head and neck cancer in southern England during 1961-98. J Oral Pathol Med, 32: 443-449, 2003.
46. Herranz Gonzalez-Botas J, Sarandeses Garcia A, Vazquez Barro C, Lopez Amado M: Second primary tumors in patients with carcinoma of the head and neck. Acta Otorrinolaringol Esp, 51: 149-153, 2000.
47. Yamamoto E, Shibuya H, Yoshimura R, Miura M: Site specific dependency of second primary cancer in early stage head and neck squamous cell carcinoma. Cancer, 94: 2007-2014, 2002.
48. Erkal HS, Mendenhall WM, Amdur RJ, Villaret DB, Stringer SP: Synchronous and metachronous squamous cell carcinomas of the head and neck mucosal sites. J Clin Oncol, 19: 1358-1362, 2001.
49. Di Martino E, Rieger M, Hassan HA, Hausmann R, Reinecke T, Lohmann M, Westhofen M: Multiple primary carcinomas in patients with head and neck malignancies. Laryngorhinootologie, 79: 711-718, 2000.
50. Di Martino E, Sellhaus B, Hausmann R, Minkenberg R, Lohmann M, Esthofen MW: Survival in second primary malignancies of patients with head and neck cancer. J Laryngol Otol, 116: 831-838, 2002.
51. Rafferty MA, O'Dwyer TP: Secondary primary malignancies in head and neck squamous cell carcinoma. J Laryngol Otol, 115: 988-991, 2001.
52. Schwager K, Nebel A, Baier G, Hoppe F: Second primary carcinomas in the upper aerodigestive tract in different locations and age groups. Laryngorhinootologie, 79: 599-603, 2000.
53. Suzuki T, Takahashi H, Yao K, Inagi K, Nakayama M, Makoshi T, Nagai H, Okamoto M: Multiple primary malignancies in the head and neck: a clinical review of 121 patients. Acta Otolaryngol, 547 (Suppl 1): 88-92, 2002.
54. Aydiner A, Karadeniz A, Uygun K, Tas S, Tas F, Disci R, Topuz E: Multiple primary neoplasms at a single institution: differences between synchronous and metachronous neoplasms. Am J Clin Oncol, 23: 364-370, 2000.
55. Do KA, Johnson MM, Doherty DA, Lee JJ, Wu XF, Dong Q, Hong WK, Khuri FR, Fu KK, Spitz MR: Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol. Cancer Causes Control, 14: 131-138, 2003.
56. Cloos J, Leemans CR, van der Sterre ML, Kuik DJ, Snow GB, Braakhuis BJ: Mutagen sensitivity as a biomarker for second primary tumors after head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev, 9: 713-717, 2000.
57. Khuri FR, Kim ES, Lee JJ, Winn RJ, Benner SE, Lippman SM, Fu KK, Cooper JS, Vokes EE, Chamberlain RM, Williams B, Pajak TF, Goepfert H, Hong WK: The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev, 10: 823-829, 2001.
58. Van Oijen MG, Leppers-van de Straat FG, Tilanus MG, Slootweg PJ: The origins of multiple squamous cell carcinomas in the aerodigestive tract. Cancer, 88: 884-893, 2000.
59. Tomek MS, McGuirt WF: Second head and neck cancers and tobacco usage. Am J Otolaryngol, 24: 24-27, 2003.
60. Vaamonde P, Martin C, del Rio M, LaBella T: Second primary malignancies in patients with cancer of the head and neck. Otolaryngol Head Neck Surg, 129: 65-70, 2003.
61. Douglas WG, Rigual NR, Loree TR, Wiseman SM, Al-Rawi S, Hicks WL Jr: Current concepts in the management of a second malignancy of the lung in patients with head and neck cancer. Curr Opin Otolaryngol Head Neck Surg, 11: 85-88, 2003.
62. Roullet MH, Wind P, Zinzindohoue F, Laccourreye O, Berger A, Chevallier JM, Bonfils P, Brasnu D, Cugnenc PH: Esophagectomy for squamous cell carcinoma of the esophagus isolated or associated with head and neck cancer: long-term survival. Ann Chir, 126: 526-534, 2001.
63. Mariette C, Fabre S, Balon JM, Finzi L, Chevalier D, Triboulet JP: Oesophageal cancer in patients with head and neck cancers: therapeutic implications. Ann Chir, 127: 757-764, 2002.
64. Warner GC, Cox GJ: Evaluation of chest radiography versus chest computed tomography in screening for pulmonary malignancy in advanced head and neck cancer. J Otolaryngol, 32: 107-109, 2003.
65. Arunachalam PS, Putnam G, Jennings P, Messersmith R, Robson AK: Role of computerized tomography (CT) scan of the chest in patients with newly diagnosed head and neck cancers. Clin Otolaryngol, 27: 409-411, 2002.
66. De Bree R, Deurloo EE, Snow GB, Leemans CR: Screening for distant metastases in patients with head and neck cancer. Laryngoscope, 110: 397-401, 2000.
67. Stoeckli SJ, Zimmermann R, Schmid S: Role of routine panendoscopy in cancer of the upper aerodigestive tract. Otolaryngol Head Neck Surg, 124: 208-212, 2001.
68. Murakami S, Hashimoto T, Noguchi T, Shimabukuro Y, Kitamura M, Nozaki T, Terashima A, Asano T, Okada H: The utility of endoscopic screening for patients with esophageal or head and neck cancer. Dis Esophagus, 12: 186-190, 1999.
69. O'Meara WP, Thiringer JK, Johnstone PA: Follow-up of head and neck cancer patients post-radiotherapy. Radiother Oncol, 66: 323-326, 2003.
70. Tabor MP, Brakenhoff RH, van Houten VM, Kummer JA, Snel MH, Snijders PJ, Snow GB, Leemans CR, Braakhuis BJ: Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res, 7: 1523-1532, 2001.
71. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Van Der Wal JE, Snow GB, Leemans CR, Braakhuis BJ: Multiple head and neck tumors frequently originate from a single preneoplastic lesion. Am J Pathol, 161: 1051-1060, 2002.
72. Leoni-Parvex S, Mihaescu A, Pellanda A, Monnier P, Bosman FT: Esophageal cytology in the follow-up of patients with treated upper aerodigestive tract malignancies. Cancer, 90: 10-16, 2000.
73. Tincani AJ, Brandalise N, Altemani A, Lopes LR, Montes CG, Altemani A, Martins AS: Diagnosis of superficial esophageal cancer and dysplasia using endoscopic screening with a 2% lugol dye solution in patients with head and neck cancer. Head Neck, 22: 170-174, 2000.
74. Scherubl H, von Lampe B, Faiss S, Daubler P, Bohlmann P, Plath T, Foss HD, Scherer H, Strunz A, Hoffmeister B, Stein H, Zeitz M, Riecken EO: Screening for oesophageal neoplasia in patients with head and neck cancer. Br J Cancer, 86: 239-243, 2002.
75. Petit T, Georges C, Jung GM, Borel C, Bronner G, Flesch H, Massard G, Velten M, Haegele P, Schraub S: Systematic esophageal endoscopy screening in patients previously treated for head and neck squamous-cell carcinoma. Ann Oncol, 12: 643-646, 2001.
76. Homann N, Nees M, Conradt C, Dietz A, Weidauer H, Maier H, Bosch FX: Overexpression of p53 in tumor-distant epithelia of head and neck cancer patients is associated with an increased incidence of second primary carcinoma. Clin Cancer Res, 7: 290-296, 2001.
77. Hattori K, Inohara H, Sawada T, Honjo Y, Yoshida J, Kubo T: Association of p53 expression with second primary tumour development in hypopharyngeal carcinoma. J Laryngol Otol, 114: 198-201, 2000.
78. Sardi I, Franchi A, Bocciolini C, Mechi C, Frittelli A, Bruschini L, Gallo O: Microsatellite instability as biomarker for risk of multiple primary malignancies of the upper aerodigestive tract. Oncol Rep, 8: 393-399, 2001.
79. Esser D, Anke S, Roessner A, Kusakabe M, Rudolph R, Bohm G: Second carcinomas in cancers of the mouth cavity, pharynx and larynx. Clinical, histopathologic and cell kinetic findings. Laryngorhinootologie, 79: 478-482, 2000.
80. Blons H, Laurent-Puig P: TP53 and head and neck neoplasms. Hum Mutat, 21: 252-257, 2003.
81. Alsner J, Sorensen SB, Overgaard J: TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother Oncol, 59: 179-185, 2001.
82. Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Soussi T, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P: p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol, 18: 1465-1473, 2000.
83. Temam S, Flahault A, Perie S, Monceaux G, Coulet F, Callard P, Bernaudin JF, St Guily JL, Fouret P: p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol, 18: 385-394, 2000.
84. Allal AS, Taussky D, Mach N, Becker M, Bieri S, Dulguerov P: Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience. Int J Radiat Oncol Biol Phys, 58: 1431-1436, 2004.
85. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M; European Organization for Research and Treatment of Cancer Trial 22931: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med, 350: 1945-1952, 2004.
86. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK; Radiation Therapy Oncology Group 9501/Intergroup: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med, 350: 1937-1944, 2004.